Belgium-based additive manufacturer and 3D printing company Materialise said today it inked a deal with Tissue Regeneration Systems to create 3D-printed tracheal splints for use in clinical trials.
Materialise said its Mimics Innovation Suite was used to design the stent, constructed from a bioresorbable platform licensed to TRS from the University of Michigan in 2007.
“The collaboration between TRS and Materialise will provide production capacity for the tracheal splint, which will allow the splint to be available to a larger number of infants who are affected with TBM,” Materialise managing director Bryan Crutchfield said in prepared remarks.
TRS received its 1st commercial product clearance from the FDA in 2013 after years refining its fabrication methods, the company said. TRS’ partnership with Materialise is one of several co-development projects it has underway.
The splints have been given an FDA investigational device exemption to treat tracheobronchomalacia, the companies said.
“We are excited to have the opportunity to impact the lives of children affected with TBM through the production of the tracheal splint,” TRS CEO Jim Fitzsimmons said in prepared remarks.
